Abstract:Background: Achieving the maximum reduction in cardiovascular morbidity and mortality is the primary goal of blood pressure (BP) control. Current guidelines recommend several antihypertensive classes as first-line therapy for this purpose but the decision on which agent/s to use will likely be based upon the treating physician's clinical experience. Observational studies provide a useful way of ascertaining the efficacy and tolerability of an antihypertensive in a real-life clinical setting. Objective: The aim of this observational study was to determine the efficacy, tolerability and physician/patient satisfaction with long-acting nifedipine (gastrointestinal therapeutic system [GITS]/osmotic-controlled release oral delivery system [OROS]) in a large multinational cohort of hypertensive patients. Methods: This observational study was conducted in adults (aged >= 18 years) with previously untreated or treated hypertension. The decision to prescribe nifedipine 30 or 60 mg once daily was made by the treating physician. Patients then attended up to three clinic visits any time over a 12-week period when medication could be up- or down-titrated or switched. The mean reduction in systolic BP (SBP)/diastolic BP (DBP) from first visit and whether target BP (<140/<90 mmHg or <130/<80 mmHg [for patients with diabetes mellitus]) had been achieved were recorded at the final visit and stratified according to hypertension grade and presence of cardiovascular risk factors. Subjective assessment of efficacy was reported by physicians and patients. All adverse events and their possible relationship to study drug were recorded. All assessments were performed on patients who received at least one dose of nifedipine GITS/OROS. Results: A total of 14 344 patients received nifedipine GITS/OROS treatment (58.7% male; 77.7% non-diabetic; mean age 57.5 years); 14 266 had at least one follow-up visit over a mean 10.2-week period, and 8000 patients had three visits over a mean 12-week period. Initially, 12 826 (89.4%) patients received nifedipine 30 mg, and 6912 patients (48.2%) overall received concomitant antihypertensive agents. The overall mean reduction in SBP/DBP was -27.7/-14.1 mmHg; BP reduction was linked to hypertension grade, age, the presence of five or more cardiovascular risk factors, and prior treatment. Target BP was achieved in 2485/7432 patients (33.4%) receiving nifedipine GITS/OROS monotherapy and in 1751/6912 (25.3%) receiving combination therapy (i.e. GITS/OROS plus any other antihypertensive agent). Non-diabetic patients with moderate (n = 3413) and high (n=1138) risk reached their target BP goal in 62.5% and 54.2% of cases, respectively; the corresponding values in diabetic patients (moderate-added risk n = 8; high-added risk n = 684) were 75.0% and 54.8%, respectively. A total of 229 patients (1.6%) reported experiencing 286 adverse events. Physician/patient satisfaction with treatment was high. Conclusion: Long-acting nifedipine GITS/OROS, alone or in combination with other antihypertensive agents, provides effective and well tolerated treatment of hypertension in a broad spectrum of patients routinely seen in day-to-day clinical practice.

Toleration of compound nitrendipine tablets in healthy volunteers after a single oral administration

Research on tolerance of compound nitrendipine tablets in healthy volunteers after successive oral administration

Efficacy of Different Doses of Nitroglycerin Combined with Clopidogrel in the Treatment of Angina Pectoris

Effect of Atenolol on the Pharmacokinetics of Nitrendipine in Healthy Volunteers

Multicenter Clinical Trial on Benidipine in the Treatment of Stable Angina Pectoris

Randomized, double-blind, parallel controlled,multicentre clinical trial of fixed combination of nitrendipine and atenolol in the treatment of mild to moderate essential hypertension

Efficacy and Safety of Fixed Combination of Nitrendipine and Atenolol in Treatment for Patients with Mild to Moderate Essential Hypertension and Their Optimal Dosage Matching

[PP.02.03] EFFICACY AND TOLERABILITY OF NIFEDIPINE GASTROINTESTINAL THERAPEUTIC SYTEM 60MG IN CHINESE PATIENTS WITH UNCONTROLLED HYPERTENSION

Comparison of Therapeutic Efficacy between Cilnidipine and Nitrendipine in the Treatment of Hypertension

Pharmacokinetics and Bioequivalence of Domestic Nisoldipine Tablets in Healthy Volunteers

Long-action antihypertensive efficacy of Benidipine in patients with mild to moderate hypertension:an open-label,ambulatory blood pressure monitoring and long-term study

EFFECT OF ANGIOTENSIN II RECEPTOR ANTAGONIST AND ENDOTHELIN RECEPTOR ANTAGONIST ON NITROGLYCERIN TOLERANCE IN RATS

The Effect of Losartan Treatment on Nitroglycerin Tolerance in Rats

Efficacy and tolerability of long-acting nifedipine GITSOROS monotherapy or combination therapy in hypertensive patients: Results of a 12-week international, prospective, multicentre, observational study

Studies on in Vivo and in Vitro Dissolution of Nitrendipine Delayed Release Tablets

Comparative Bioequivalence and Food Effect of Two Formulations of 30‐mg Nifedipine Controlled‐Release Tablets in Healthy Chinese Adults

The Efficacy and Safety of the Compound Felodipine Sustained-Release Tablets in Mild to Moderate Essential Hypertension: a Double-Blind Randomized Clinical Trials

Effects of Compound Hypotensive Tablets Administered at Different Time Points on Pressure Rhythm and 24-Hour Ambulatory Blood Pressure in Patients with Non-dipper Essential Hypertension

Short-term effectiveness and safety of Compound Anti-Hypertensive Tablets (No.0) in patients with primary hypertension

The Safety and Tolerance of Herbal Anti-Angina Drug Compound Danshen Droplet Pill in Healthy Volunteers

Toleration of vardenafil tablets in healthy volunteers after a single oral administration